Meriden, Conn--A 5-year study at Walter Reed Army Institute of Research found no significant clinical benefit for patients receiving MicroGenesys, Inc's therapeutic AIDS vaccine,VaxSyn rpg 160,compared with placebo, the company has announced.
Preiminary analysis of data from the phase II study, conducted in more than 600 HIV-infected volunters, demonstrated the saftey of VaxSyn. According to the company, these data indicate that MicroGeneSys's proprietary baculovirus expression vector system (BEVS) is a safe process for manufacturing human biologics that are to be used in large numbers of patients receiving frequent injections over a long period of time.
"Although there were no statistically significant differences in clinical events,there were certain modest and time limited effects favoring VaxSyn. Further data analysis are being done that may show that some groups of patients may have responded favorably to treatment with VaxSyn," the company said.